Paolo Sirtori
Research Subjects
Paolo Sirtori has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Rubinacci
Ospedale San Raffaele-Respighi, 20121 Milano, Italy
4 shared publications Corrado Sosio
1 shared publicationD. Fern
WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, UK
1 shared publicationEmanuela Mrak
1 shared publication- Eugene V. McCloskey
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
1 shared publication Francesca Guidobono
1 shared publication
Latest Publications
- 1 September 1997
- Published by Elsevier in Pharmacological Research
- Vol. 36 (3) , 229-235
A COMPARATIVE STUDY ON BIOCHEMICAL MARKERS OF BONE COLLAGEN BREAKDOWN IN POST-MENOPAUSAL WOMEN
- 1 September 1997
- Published by Elsevier in Pharmacological Research
- Vol. 36 (3) , 229-235
A COMPARATIVE STUDY ON BIOCHEMICAL MARKERS OF BONE COLLAGEN BREAKDOWN IN POST-MENOPAUSAL WOMEN
- 1 June 1996
- Published by Elsevier in Pharmacological Research
- Vol. 33 (6) , 353-359
EFFECT OF SHORT COURSE OF 1,25-DIHYDROXYVITAMIN D3ON BIOCHEMICAL MARKERS OF BONE REMODELLING IN POSTMENOPAUSAL WOMEN
- 1 June 1996
- Published by Elsevier in Pharmacological Research
- Vol. 33 (6) , 353-359
EFFECT OF SHORT COURSE OF 1,25-DIHYDROXYVITAMIN D3ON BIOCHEMICAL MARKERS OF BONE REMODELLING IN POSTMENOPAUSAL WOMEN
- 1 March 1996
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 19 (3) , 154-158
Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy
Aim of the study was to compare urinary galactosyl-hydroxylysine (GHyl), deoxypyridinoline (D-Pyr) and pyridinoline (Pyr) before and after 5 to 9 months of hormone replacement therapy (HRT) in postmenopausal women. The urinary markers were measured by HPLC in the second void of fasting samples and were expressed as ratio to creatinine. GHyl was also expressed as a ratio to glucosylgalactolysyl-hydroxylysine (GGHyl). After short-term hormone replacement therapy, urinary D-Pyrfell significantly, but Pyr and GHyl, also when expressed as a ratio to GGHyl, remained unmodified. We conclude that GHyl and Pyr are not useful markers in monitoring the bone response to HRT in postmenopausal women.
- 1 March 1996
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 19 (3) , 154-158
Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy
Aim of the study was to compare urinary galactosyl-hydroxylysine (GHyl), deoxypyridinoline (D-Pyr) and pyridinoline (Pyr) before and after 5 to 9 months of hormone replacement therapy (HRT) in postmenopausal women. The urinary markers were measured by HPLC in the second void of fasting samples and were expressed as ratio to creatinine. GHyl was also expressed as a ratio to glucosylgalactolysyl-hydroxylysine (GGHyl). After short-term hormone replacement therapy, urinary D-Pyrfell significantly, but Pyr and GHyl, also when expressed as a ratio to GGHyl, remained unmodified. We conclude that GHyl and Pyr are not useful markers in monitoring the bone response to HRT in postmenopausal women.
- 9 October 1993
- Published by Wiley in Acta Paediatrica
- Vol. 82 (9) , 711-713
Is there an impact of birth weight and early life nutrition on bone mineral content in preterm born infants and children?
- 9 October 1993
- Published by Wiley in Acta Paediatrica
- Vol. 82 (9) , 711-713
Is there an impact of birth weight and early life nutrition on bone mineral content in preterm born infants and children?
- 1 March 1993
- Published by Springer Nature in Osteoporosis International
- Vol. 3 (S2) , 23-28
Rationale for the use of clodronate in osteoporosis
Bisphosphonates are widely used in disorders associated with increased resorption of bone, particularly in Paget's disease of bone and in the hypercalcemia of malignancy. Because of their undoubted efficacy and relatively low toxicity, bisphosphonates are attractive candidates for the management of osteoporosis. Clodronate, one of the many bisphosphonates being tested in osteoporosis, may be given intravenously or by mouth. In contrast to etidronate, even high doses of clodronate do not impair the mineralization of bone, making it suitable for long-term use in osteoporosis. As do all the bisphosphonates tested thus far, clodronate appears to delay the rate of bone loss in osteoporosis. Long-term studies are relatively few, so that its steady-state effects on bone mass are not yet known. Most data suggest clodronate is capable at least of delaying the rate of bone loss, but several pilot studies with this agent suggest that increments of bone mass might be sustainable for several years. Clodronate is likely to decrease the frequency of osteoporotic fractures, but there is no evidence for this at present. Well-controlled, long-term prospective studies are needed.
- 1 March 1993
- Published by Springer Nature in Osteoporosis International
- Vol. 3 (S2) , 23-28
Rationale for the use of clodronate in osteoporosis
Bisphosphonates are widely used in disorders associated with increased resorption of bone, particularly in Paget's disease of bone and in the hypercalcemia of malignancy. Because of their undoubted efficacy and relatively low toxicity, bisphosphonates are attractive candidates for the management of osteoporosis. Clodronate, one of the many bisphosphonates being tested in osteoporosis, may be given intravenously or by mouth. In contrast to etidronate, even high doses of clodronate do not impair the mineralization of bone, making it suitable for long-term use in osteoporosis. As do all the bisphosphonates tested thus far, clodronate appears to delay the rate of bone loss in osteoporosis. Long-term studies are relatively few, so that its steady-state effects on bone mass are not yet known. Most data suggest clodronate is capable at least of delaying the rate of bone loss, but several pilot studies with this agent suggest that increments of bone mass might be sustainable for several years. Clodronate is likely to decrease the frequency of osteoporotic fractures, but there is no evidence for this at present. Well-controlled, long-term prospective studies are needed.